Insider Transactions

What Rhythm Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.

Insider trades

	3 months	12 months
Open-market buys	0	0
Sells	20	52
Total trades	26	101

Shares traded

	3 months	12 months
Acquired	212,437	530,408
Disposed	258,450	437,892
Net activity	−46,013	+92,516

See the story behind these numbers

View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.

Open-market buyer Disclosed 10b5-1 Heavy discretionary Sign up free

All transactions

All Buys Sells

Insider	Relation	Date	Transaction	Shares	Price	Value	Shares held
Meeker David P	President and CEO	Sep 14	Disclosed 10b5-1 sale · S	−2,300	$105.19	−$242K	239,258
Meeker David P	President and CEO	Sep 14	Disclosed 10b5-1 sale · S	−1,817	$104.55	−$190K	241,558
Meeker David P	President and CEO	Sep 14	Disclosed 10b5-1 sale · S	−8,698	$103.43	−$900K	243,375
Meeker David P	President and CEO	Sep 14	Disclosed 10b5-1 sale · S	−30,746	$102.35	−$3.15M	252,073
Meeker David P	President and CEO	Sep 14	Disclosed 10b5-1 sale · S	−6,439	$101.75	−$655K	282,819
Meeker David P	President and CEO	Sep 14	Exercise / conversion · M	+50,000	$6.05	+$303K	289,258
Smith Hunter C	Chief Financial Officer	Aug 31	Disclosed 10b5-1 sale · S	−28,188	$106.20	−$2.99M	114,024
Smith Hunter C	Chief Financial Officer	Aug 31	Disclosed 10b5-1 sale · S	−11,514	$105.37	−$1.21M	142,212
Smith Hunter C	Chief Financial Officer	Aug 31	Disclosed 10b5-1 sale · S	−23,072	$104.59	−$2.41M	153,726
Smith Hunter C	Chief Financial Officer	Aug 31	Exercise / conversion · M	+57,187	$25.79	+$1.47M	176,798
Chien Jennifer	EVP, Head of North America	Aug 13	Open-market sale · S	−75,834	$117.38	−$8.9M	0
Chien Jennifer	EVP, Head of North America	Aug 13	Exercise / conversion · M	+21,601	$6.80	+$147K	75,834
Chien Jennifer	EVP, Head of North America	Aug 13	Exercise / conversion · M	+35,000	$24.29	+$850K	54,233
Garfield Alastair	Chief Scientific Officer	Aug 13	Open-market sale · S	−800	$119.17	−$95.3K	2,295
Garfield Alastair	Chief Scientific Officer	Aug 13	Open-market sale · S	−3,400	$118.28	−$402K	3,095
Garfield Alastair	Chief Scientific Officer	Aug 13	Open-market sale · S	−1,556	$117.08	−$182K	6,495
Garfield Alastair	Chief Scientific Officer	Aug 13	Open-market sale · S	−2,007	$116.11	−$233K	8,051
Shulman Joseph	Chief Technical Officer	Aug 13	Open-market sale · S	−5,079	$119.75	−$608K	15,915
Shulman Joseph	Chief Technical Officer	Aug 13	Exercise / conversion · M	+2,024	$6.80	+$13.8K	20,994
Mazabraud Yann	EVP, Head of International	Aug 12	Disclosed 10b5-1 sale · S	−17,319	$117.47	−$2.03M	55,655

Page 1 of 30 · showing the 20 most recent Sign up free to view all 583 transactions and filter by insider →

Comments